Lupin Recalls Tydemy Birth Control Pills Amid Effectiveness Concerns

Thu Aug 03 2023
icon-facebook icon-twitter icon-whatsapp

NEW JERSEY: Drug manufacturer Lupin, responsible for the birth control pill Tydemy, is conducting a recall of two batches of the medication due to potential decreased effectiveness.

Lupin, based in New Jersey, announced on Saturday that it is recalling these batches after tests revealed lower levels of ascorbic acid, an inactive ingredient, and elevated levels of a “known impurity.”

The company’s statement highlights that this situation could impact the product’s efficacy, potentially leading to unexpected pregnancies.

The Food and Drug Administration (FDA) issued a similar caution to consumers on Tuesday about the reduced levels of ascorbic acid (vitamin C) in the Tydemy pills, which may compromise their ability to prevent pregnancy.

Both Lupin and the FDA clarified that they have not received any reports of adverse effects associated with the pills’ use.

The affected batches were distributed between June 3, 2022, and May 31 of this year, with expiration dates of January or September 2024.

Lupin’s Advisory for Tydemy Users

Lupin’s press release advises current Tydemy users to continue their usage for now. However, the company strongly recommends that they promptly seek advice from their pharmacist, physician, or medical provider regarding alternative treatment options. Unfortunately, the company did not immediately respond to inquiries seeking further details about the impurity and the role of ascorbic acid in it.

The batches subject to recall can be identified by the lot numbers displayed on the packaging. One batch, comprising a 28-pill pack, is associated with lot number L200183, while the other, containing three packs of 28 pills, is linked to lot number L201560.

Patients experiencing complications while using the pill are encouraged to contact their healthcare provider and report their concerns through the FDA’s MedWatch Adverse Event Reporting program, as outlined in Lupin’s announcement.

Furthermore, the company has requested that pharmacists and retailers cease distribution of the recalled product lots without delay.

icon-facebook icon-twitter icon-whatsapp